POWERING THE IMMUNE SYSTEM TO TRANSFORM LIVES | --- | --- | --- | |--------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Vir Biotechnology Q2:24 | | | | | | | | Investor Conference Call | | | | | | | | | | | | | | | | | | | | | | | | | | | | August 1st 2024 | | | © 2024 Vir Biotechnology, Inc. 1 Legal Disclaimer Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-loo ...

Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Jennifer Towne - Executive Vice President and Chief Scientific Officer Mark Eisner - Executive Vice President and Chief Medical Officer Brent Sabatini - Chief Accounting Officer Conference Call Participants Phil Nadeau - TD Cowen Nikola Gasic - Leerink Paul Choi - Goldman Sachs Eric Joseph - J.P. ...

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.45 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -9.68%. A quarter ago, it was expected that this company would post a loss of $0.99 per share when it actually produced a loss of $0.48, delivering a surprise of 51.52%. Over the last four quarters, the company has ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 __________________________________________________________ FORM 10-Q __________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________to | --- | --- ...

Exhibit 99.1 Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities – Positive preliminary Phase 2 chronic hepatitis delta study data presented at EASL™ Congress 2024, FDA IND clearance with Fast Track Designation received underscoring the potential of combination therapy – – Exclusive license agreement with Sanofi bolsters clinical pipeline – – Strategic workforce restructuring and phasing out of influenza, C ...

Strong Buy: Conclusion Overall, VIR is a promising biotech targeting hepatitis, HIV, and COVID-19. It also has a valuable mAb platform that can potentially generate consistent contract revenues that could help it fund its research programs. This investment has competitive, clinical trial, and regulatory risks, but despite these, I consider VIR's compelling valuation to provide more upside than downside at this stage. Thus, I rate VIR a "strong buy" for investors who understand the inherent risks. Editor's N ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 __________________________________________________________ FORM 10-Q __________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________to Commission ...

Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Carrie Huang - Senior Vice President, Clinical Research and Interim Chief Medical Officer Sung Lee - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Alec Stranahan - Bank of America Phil Nadeau - TD Cowen Patrick Trucchio ...

– $1.51 billion in cash, cash equivalents and investments as of March 31, 2024 – – Conference call scheduled for May 2, 2024 at 1:30 p.m. PT / 4:30 p.m. ET – SAN FRANCISCO, May 2, 2024 – Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. "We are excited to share important data from our Phase 2 chronic hepatitis delta SOLSTICE trial at the upcoming EASL congress. This milestone brings us closer to addressing the s ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-K ________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 1-39083 _____________ ...